Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis

47Citations
Citations of this article
65Readers
Mendeley users who have this article in their library.

Abstract

CFTR modulators have revolutionized the treatment of individuals with cystic fibrosis (CF) by improving the function of existing protein. Unfortunately, almost half of the disease-causing variants in CFTR are predicted to introduce premature termination codons (PTC) thereby causing absence of full-length CFTR protein. We hypothesized that a subset of nonsense and frameshift variants in CFTR allow expression of truncated protein that might respond to FDA-approved CFTR modulators. To address this concept, we selected 26 PTC-generating variants from four regions of CFTR and determined their consequences on CFTR mRNA, protein and function using intron-containing minigenes expressed in 3 cell lines (HEK293, MDCK and CFBE41o-) and patient-derived conditionally reprogrammed primary nasal epithelial cells. The PTC-generating variants fell into five groups based on RNA and protein effects. Group A (reduced mRNA, immature (core glycosylated) protein, function <1% (n = 5)) and Group B (normal mRNA, immature protein, function <1% (n = 10)) variants were unresponsive to modulator treatment. However, Group C (normal mRNA, mature (fully glycosylated) protein, function >1% (n = 5)), Group D (reduced mRNA, mature protein, function >1% (n = 5)) and Group E (aberrant RNA splicing, mature protein, function > 1% (n = 1)) variants responded to modulators. Increasing mRNA level by inhibition of NMD led to a significant amplification of modulator effect upon a Group D variant while response of a Group A variant was unaltered. Our work shows that PTC-generating variants should not be generalized as genetic ‘nulls’ as some may allow generation of protein that can be targeted to achieve clinical benefit.

References Powered by Scopus

Fast gapped-read alignment with Bowtie 2

36296Citations
N/AReaders
Get full text

TopHat: Discovering splice junctions with RNA-Seq

9630Citations
N/AReaders
Get full text

Differential analysis of gene regulation at transcript resolution with RNA-seq

2719Citations
N/AReaders
Get full text

Cited by Powered by Scopus

CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine

356Citations
N/AReaders
Get full text

Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis

79Citations
N/AReaders
Get full text

Theratyping cystic fibrosis patients to guide elexacaftor/ tezacaftor/ivacaftor out-of-label prescription

41Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Sharma, N., Evans, T. A., Pellicore, M. J., Davis, E., Aksit, M. A., McCague, A. F., … Cutting, G. R. (2018). Capitalizing on the heterogeneous effects of CFTR nonsense and frameshift variants to inform therapeutic strategy for cystic fibrosis. PLoS Genetics, 14(11). https://doi.org/10.1371/journal.pgen.1007723

Readers over time

‘18‘19‘20‘21‘22‘23‘24‘250481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 18

58%

Researcher 8

26%

Professor / Associate Prof. 4

13%

Lecturer / Post doc 1

3%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 18

58%

Medicine and Dentistry 6

19%

Agricultural and Biological Sciences 5

16%

Chemistry 2

6%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 39

Save time finding and organizing research with Mendeley

Sign up for free
0